Xeris Pharmaceuticals (NASDAQ:XERS) is engaged in developing and commercializing innovative therapies in endocrinology and neurology. The company focuses on creating products that use its proprietary formulation technology platforms, including XeriSol™ and XeriJect™, which are designed to enhance the efficacy, safety, and convenience of therapies for patients with serious and chronic medical conditions. Xeris Pharmaceuticals aims to address significant unmet medical needs by bringing to market treatments that offer better clinical outcomes and more accessible patient care. Its portfolio includes Gvoke® for severe hypoglycemia in diabetes patients, reflecting the company's commitment to improving the lives of those living with challenging medical conditions. Through ongoing research and development, Xeris seeks to expand its product offerings and deliver innovative healthcare solutions worldwide.